Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.62 |
| ▸ | ABL1 | P00519 | 11/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323230 | 0.86 | FGFR1 (0.64) | KITABL1SRC | |
| SCHEMBL15907266 | 0.84 | ABL1 (0.69) | KITABL1SRC | |
| SCHEMBL15907297 | 0.84 | KIT (0.43) | KITABL1SRC | |
| SCHEMBL15907303 | 0.84 | KIT (0.46) | KITABL1SRC | |
| Vamotinib SCHEMBL29441255 | 0.82 | ABL1 (0.80) | KITABL1SRC | |
| Vamotinib SCHEMBL15789568 | 0.82 | ABL1 (0.80) | KITABL1SRC | |
| SCHEMBL25639439 | 0.81 | ABL1 (0.69) | KITABL1 | |
| SCHEMBL15800815 | 0.81 | ABL1 (0.68) | KITABL1 | |
| SCHEMBL15800788 | 0.81 | ABL1 (0.68) | KITABL1 | |
| SCHEMBL15907256 | 0.81 | ABL1 (0.58) | KITABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | KIT 577/4885ABL1 1/4885SRC 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.